Tumor-Homing iRGD Peptide Dramatically Improves Camptothecin's Ability to Reach and Kill Colon Cancer Cells | Research

The takeaway

Conjugating the tumor-homing peptide iRGD to camptothecin dramatically improved drug penetration into colon cancer cells and tumor accumulation in mice, suppressing tumor growth more effectively than the free drug.

Enhanced tumor accumulation
iRGD-CPT conjugate showed higher tumor tissue distribution and greater antitumor effects than unconjugated camptothecin in mice

What the researchers found

iRGD-camptothecin conjugate showed superior cell penetration, greater colon cancer cell killing at micromolar concentrations, higher tumor accumulation, and enhanced antitumor effects compared to unconjugated camptothecin in both in vitro and in vivo models.

Why it matters

Camptothecin is a potent anticancer agent but suffers from poor tumor penetration and off-target toxicity. Using iRGD peptide for targeted delivery could improve the therapeutic index, delivering more drug to tumors while reducing systemic side effects.

The numbers in context

The conjugate was linked via a heterobifunctional linker. Both in vitro and in vivo studies showed improved tumor targeting.

How the study worked

In vitro: synthesized iRGD-CPT conjugate with heterobifunctional linker, tested penetration and viability in human colon cancer cells. In vivo: evaluated tumor distribution and antitumor efficacy in a mouse colon cancer model.

Who was studied

Human colon cancer cell lines and mouse tumor models

What this study cannot tell us

Single cancer type (colon cancer) tested. Mouse xenograft models don't fully replicate human tumor biology. The stability and pharmacokinetics of the conjugate in humans are unknown. Comparison was only to free drug, not to other targeting strategies.

How to read the evidence

Preliminary evidence from in vitro and in vivo preclinical studies. Demonstrates proof of concept but lacks clinical data.

When this study was published

Published in 2024. Advances the peptide-drug conjugate field for cancer therapy.

The bigger picture

Tumor-homing peptides like iRGD represent a growing strategy for improving cancer drug delivery. By exploiting the unique biology of tumor blood vessels and cancer cell surfaces, peptide-drug conjugates can achieve targeted delivery that conventional chemotherapy cannot.

Questions still open

Would iRGD-CPT be effective against other cancer types that express integrin targets?
How does the toxicity profile of the conjugate compare to free camptothecin in animal models?
Could iRGD be used to deliver other problematic anticancer compounds?

Common questions

What is iRGD and how does it find tumors?

iRGD is a small cyclic peptide that binds to integrins (proteins abundant on tumor blood vessels and cancer cells). After binding, it triggers a cell-penetration pathway that actively transports the attached drug deep into tumor tissue.

Why not just use camptothecin directly?

Camptothecin is effective at killing cancer cells but doesn't preferentially go to tumors — it distributes throughout the body, causing side effects. By attaching it to iRGD, more drug reaches the tumor and less goes to healthy tissue, potentially making treatment more effective with fewer side effects.

Read the original research

Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.

European journal of medicinal chemistry, 265, 116050

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Tejinder; Kim, Tae Wan; Murthy, Akula S N; Paul, Mohuya; Sepay, Nasim; Jeong Kong, Hye; Sung Ryu, Jae; Rim Koo, Na; Yoon, Sujeong; Song, Keon-Hyoung; Jun Baek, Moo; Jeon, Seob; Im, Jungkyun. (2024). Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.. European journal of medicinal chemistry, 265, 116050. https://doi.org/10.1016/j.ejmech.2023.116050